Paradigm shift: combination BET and JAK inhibition in myelofibrosis

Leukemia. 2021 Dec;35(12):3361-3363. doi: 10.1038/s41375-021-01405-z. Epub 2021 Sep 3.

Authors

John Mascarenhas¹, Aaron Gerds², Srdan Verstovsek³

Affiliations

¹ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. John.Mascarenhas@mssm.edu.
² Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, 44195, USA.
³ University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

PMID: 34480105
DOI: 10.1038/s41375-021-01405-z

No abstract available

MeSH terms

Animals
Humans
Janus Kinases / antagonists & inhibitors*
Primary Myelofibrosis / drug therapy*
Primary Myelofibrosis / metabolism
Primary Myelofibrosis / pathology
Protein Kinase Inhibitors / therapeutic use*
Proteins / antagonists & inhibitors*

Substances

Protein Kinase Inhibitors
Proteins
bromodomain and extra-terminal domain protein, human
Janus Kinases